Cocrystal Pharma
COCP
19 hedge funds and large institutions have $4M invested in Cocrystal Pharma in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
14% more capital invested
Capital invested by funds: $3.52M → $4M (+$482K)
0.08% less ownership
Funds ownership: 0.39% → 0.31% (-0.08%)
21% less funds holding
Funds holding: 24 → 19 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$376K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$61.7K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$30.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$12K |
| 5 |
Morgan Stanley
New York
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$805K |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$227K |
| 3 |
KeyBank National Association
Cleveland,
Ohio
|
-$121K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10K |
COCP Hedge Fund Activity: Q4 2018 in Review
19 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q4 2018, worth a combined $4M — up 14% from $3.52M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of COCP and 1 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $376K. The largest seller was Millennium Management, exiting entirely with an estimated $805K sold.
- 19 institutional investors held Cocrystal Pharma (COCP) as of Q4 2018, down from 24 in Q3 2018.
- Funds reported $4M of Cocrystal Pharma stock for Q4 2018, up 14% quarter-over-quarter.
- 1 fund opened new Cocrystal Pharma positions in Q4 2018 and 6 closed out, a net change of -5 holders.
- The largest Cocrystal Pharma buyer in Q4 2018 was Vanguard Group, an estimated $376K added.
- The largest Cocrystal Pharma seller in Q4 2018 was Millennium Management, an estimated $805K sold.
Based on aggregated 13F filings for Q4 2018.